Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations. Dickson, M., Ravi, V., Ganjoo, K. N., Iyer, G. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.15_suppl.3111

View details for Web of Science ID 000708120601285